![](/img/cover-not-exists.png)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Brose, Marcia S, Cabanillas, Maria E, Cohen, Ezra E W, Wirth, Lori J, Riehl, Todd, Yue, Huibin, Sherman, Steven I, Sherman, Eric JLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(16)30166-8
Date:
July, 2016
File:
PDF, 298 KB
english, 2016